4554
Fuji Pharma Co.,Ltd.
富士製薬工業
- Industry
- Pharmaceutical
- Market
- Prime
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Consolidated
Key metrics
Revenue(million JPY)
Sep 2021
33,990
Sep 2022
35,426
Sep 2023
40,889
Sep 2024
46,138
Sep 2025
51,677
Operating profit(million JPY)
Sep 2021
3,349
Sep 2022
3,777
Sep 2023
3,858
Sep 2024
3,880
Sep 2025
4,990
Operating profit margin(%)
Sep 2021
9.85
Sep 2022
10.66
Sep 2023
9.44
Sep 2024
8.41
Sep 2025
9.66
Profit before tax(million JPY)
Sep 2021
3,371
Sep 2022
3,723
Sep 2023
4,399
Sep 2024
8,276
Sep 2025
4,000
Profit(million JPY)
Sep 2021
2,432
Sep 2022
2,696
Sep 2023
3,435
Sep 2024
6,146
Sep 2025
3,000
Total assets(million JPY)
Sep 2021
64,239
Sep 2022
75,538
Sep 2023
85,332
Sep 2024
90,000
Sep 2025
93,405
Cash and cash equivalents(million JPY)
Sep 2021
10,199
Sep 2022
3,546
Sep 2023
2,324
Sep 2024
4,585
Sep 2025
7,245
Cash flows from operating activities(million JPY)
Sep 2021
5,993
Sep 2022
-658
Sep 2023
1,917
Sep 2024
4,151
Sep 2025
5,801
Cash flows from investing activities(million JPY)
Sep 2021
-2,345
Sep 2022
-11,271
Sep 2023
-5,240
Sep 2024
-1,658
Sep 2025
-4,219
Cash flows from financing activities(million JPY)
Sep 2021
-5,435
Sep 2022
5,094
Sep 2023
1,915
Sep 2024
-435
Sep 2025
954
Return on equity(%)
Sep 2021
6.7
Sep 2022
7.9
Sep 2023
8.9
Sep 2024
14.2
Sep 2025
6.5
Equity ratio(%)
Sep 2021
50.9
Sep 2022
47.4
Sep 2023
48.3
Sep 2024
50.6
Sep 2025
50.2
Earnings per share(JPY per share)
Sep 2021
90.54
Sep 2022
111.01
Sep 2023
141.37
Sep 2024
252.85
Sep 2025
122.94
Net assets per share(JPY per share)
Sep 2021
1,345.56
Sep 2022
1,473.73
Sep 2023
1,694.23
Sep 2024
1,873.52
Sep 2025
1,917.82
Dividend per share(JPY per share)
Sep 2021
29
Sep 2022
35
Sep 2023
37
Sep 2024
42.5
Sep 2025
45.5
Payout ratio(%)
Sep 2021
32.03
Sep 2022
31.53
Sep 2023
26.17
Sep 2024
16.81
Sep 2025
37.01
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.